Male breast cancer: a clinicopathological study of an Egyptian population (Alexandria experience).
OBJECTIVE
The purpose of this retrospective study is to evaluate the clinicopathological features and treatment results of male breast cancer presented to our tertiary referral center.


METHODS
Between January 1998 and December 2005, a total of 39 men with breast cancer treated at Alexandria Main University Hospital and their medical records were reviewed.


RESULTS
The median age of patients was 59 years. Only 3 (7.7%) patients had positive family history. All patients presented by breast swellings that were associated with axillary mass in about one third of them. Around 80% had hormone receptor positive (estrogen and/or progesterone receptors). Two third of patients had advanced T-stage (T3 and T4). Left sided breast cancer occurred in 51.3%. Infiltrating ductal carcinoma was the most common type of histology encountered and grade 2 was the predominant grade of tumor. Modified radical mastectomy was the most common (87.2%) type of surgery done followed by chemotherapy for 32 patients and loco-regional radiotherapy for 20 patients. Tamoxifen was administered in 31 patients. Distant relapse occurred in 7 patients (17.9%) and local recurrence occurred in 2 patients (5.1%). The 5-year disease-free survival (DFS) was 82% and the 5-year overall survival (OS) rate was 84%. Only negative axillary lymph node and positive hormone receptor status were significantly associated with favorable DFS and OS. T-stage, grade of tumor and type of chemotherapy given had no statistically significant impact on either DFS or OS.


CONCLUSIONS
Male breast cancer is still under-investigated and further researches are warranted.
Oncology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Maher
M
Soliman
Amethyst Radiotherapy Centre, Krakow, Poland.
Marcin
M
Hetnał
breast cancer; male
Eur J Cancer. 1995 Nov;31A(12):1960-4
8562148
Int J Breast Cancer. 2012;2012:845143
22991670
Mod Pathol. 1992 Nov;5(6):621-5
1369797
Acta Chir Scand. 1982;148(6):499-502
7158208
Breast. 2012 Jun;21(3):237-41
22300703
Cancer Biol Ther. 2014;15(12):1586-7
25535893
Ann Oncol. 2013 Jun;24(6):1434-43
23425944
Am J Clin Oncol. 1987 Feb;10(1):55-60
3825994
Anticancer Res. 1997 May-Jun;17(3C):2335-8
9245247
World J Surg. 1980 Sep;4(5):621-3
7233931
Int J Cancer. 1993 Feb 20;53(4):538-49
8436428
Ann Surg. 1978 Jul;188(1):60-5
208472
Surgery. 1999 Oct;126(4):775-80; discussion 780-1
10520928
Cancer. 1988 Oct 15;62(8):1632-6
3167777
Ann Intern Med. 2002 Oct 15;137(8):678-87
12379069
Cancer. 2013 May 1;119(9):1611-7
23341341
Surg Gynecol Obstet. 1972 Jun;134(6):1011-9
4338101
Eur J Surg Oncol. 1998 Dec;24(6):548-52
9870732
Ann Surg. 1992 May;215(5):451-7; discussion 457-9
1319699
Indian J Surg Oncol. 2012 Sep;3(3):245-9
23997516
World J Surg. 1983 Mar;7(2):281-7
6868642
Am J Clin Pathol. 1999 Jan;111(1):59-69
9894455
Surgery. 1994 Mar;115(3):402-5
8128366
Cancer Genomics Proteomics. 2016 May-Jun;13(3):183-90
27107060
Cancer. 2004 Jul 1;101(1):51-7
15221988
Oncologist. 2005 Aug;10(7):471-9
16079314
Clin Cancer Res. 2003 Oct 1;9(12):4452-9
14555518
Cancer. 1982 Oct 15;50(8):1664-7
6288222
BMC Cancer. 2014 Mar 28;14:227
24673740